Ask AI
ProCE Banner Activity

Why B7-H3 Is a Clinically Relevant Target in ES-SCLC

Slideset

Downloadable slides to learn more about why B7-H3 is a clinically relevant target in ES-SCLC, and gain more insight into the biology and promising investigational agents such as ifinatamab deruxtecan (I-DXd) targeting B7-H3 in ES-SCLC.

Released: October 27, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by educational grants from Daiichi Sankyo, Inc. and Merck Sharp & Dohme LLC.

Daiichi Sankyo, Inc.

Merck Sharp & Dohme LLC

Target Audience

This activity is intended for oncologists, pulmonologists, nurses, pharmacists, physician associates, and other healthcare professionals who care for patients with extensive-stage small-cell lung cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Differentiate B7-H3–directed ADCs from other available and emerging ES-SCLC strategies, including DLL3-directed T-cell engagement, chemotherapy-based approaches, maintenance strategies, and clinical trials, based on mechanism, evidence strength, toxicity profile, and operational feasibility

  • Apply emerging efficacy and safety data for investigational B7-H3–directed ADCs to patient-specific treatment planning after platinum-based therapy, including considerations related to platinum-free interval, disease tempo, brain metastases, ECOG performance status, pulmonary comorbidity, prior thoracic radiation, marrow reserve, prior therapy, and access to specialized monitoring

  • Implement practical monitoring and management strategies for ADC-associated adverse events, including ILD/pneumonitis, cytopenias, gastrointestinal adverse events, fatigue, and infusion-related considerations

  • Use case-based decision-making to formulate sequencing, referral, and multidisciplinary management strategies for patients with relapsed ES-SCLC